

1 **Factors associated with viral load suppression and indicators of stigma among people**  
2 **living with HIV in Dar es Salaam tertiary hospitals, Tanzania**

3 Mary Spicar Kilapilo<sup>1</sup>, Idda Hubert Mosh<sup>2</sup>, George Msema Bwire<sup>1</sup>, Godfrey Leonard Sambayi<sup>3</sup>,  
4 Raphael Zozimus Sangeda<sup>1\*</sup>, Japhet Killewo<sup>4</sup>

5

6 <sup>1</sup>Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied  
7 Sciences, Dar es Salaam, Tanzania.

8 <sup>2</sup>Department of Behavioural Sciences, Muhimbili University of Health and Allied Sciences, Dar  
9 es Salaam, Tanzania.

10 <sup>3</sup>Department of Pharmacognosy, Muhimbili University of Health and Allied Sciences, Dar es  
11 Salaam, Tanzania.

12 <sup>4</sup>Department of Biostatistics and Epidemiology, Muhimbili University of Health and Allied  
13 Sciences, Dar es Salaam, Tanzania.

14 Correspondence author:

15 Email: [sangeda@gmail.com](mailto:sangeda@gmail.com) (RZS)

16

17

## 18 **Abstract**

19 Perception of stigma can contribute to virological failure among people living with HIV (PLHIV).  
20 This study was conducted to assess the effect of stigmatization and self-discrimination on viral  
21 load suppression among PLHIV at tertiary hospitals in Dar es Salaam, Tanzania. This was a  
22 hospital-based cross-sectional study conducted in Temeke Regional Referral Hospital (RRH) and  
23 Amana RRH at the Care and Treatment Clinic (CTC) between July and August 2020 using a  
24 structured questionnaire with open and close-ended questions. Factors for stigmatization and viral  
25 load suppression were compared using the Chi-square test, while factors for viral load suppression  
26 were analyzed using multinomial logistic regression analysis. Altogether, 406 PLHIV participated,  
27 with most female respondents, 298 (73.2%). The majority (50%) were aged between 25 and 44  
28 years, whereas 171 (42.5%) respondents were married. Most of the participants, 382 (94.6%), were  
29 on a dolutegravir-based regimen, with the majority, 215 (52.8%), having a refilling interval of  
30 three months. The majority of the respondents, 379 (93.1%), disclosed their status. Most  
31 participants, 355 (87.4%), preferred having a separate HIV clinic, while 130 (32.1%) participants  
32 were not ready to be attended by the health care workers (HCWs) familiar to them. Male patients  
33 were 60% less likely to suppress their viral load as compared to female patients (adjusted odds  
34 ratio [aOR]: 0.4, 95% confidence interval [95%]: 0.19 – 0.77,  $p = 0.007$ ). Refill interval was  
35 significantly associated with viral load suppression. For example, patients with a one-month refill  
36 interval had odds of 0.01 (95% CI: 0.003-0.42,  $p < 0.0001$ ) compared to six-month refill intervals.  
37 Stigmatization elements appeared to influence the viral load suppression among PLHIV. Factors  
38 such as gender and refill time interval were significantly associated with viral load suppression  
39 among HIV patients in the Dar es Salaam region.

40           Keywords: Self-discrimination, Stigmatization, Dolutegravir, Dar es Salaam, HIV, viral  
41           load suppression, people living with HIV, Tanzania

## 42   **Introduction**

43   Viral load suppression indicates disease progression, wellness, antiretroviral therapy (ART)  
44   effectiveness and minimized HIV drug resistance (HIVDR). On the other hand, virological failure  
45   indicates the inverse and is associated with HIVDR [1]. Upon characterization of the factors  
46   contributing to non-adherence, stigmatization was found to have a major link with non-adherence  
47   [2,3].

48   PLHIV continue to suffer from stigma and discrimination from their family and communities.  
49   Evidence from research suggests that HIV-related stigma and self-stigmatization result in a delay  
50   in the disclosure of HIV serostatus, which is a potential barrier to HIV counseling, retention in  
51   care and treatment, and uptake of and adherence to ART [4]. AIDS-related stigma and  
52   discrimination impede millions of PLHIV from accessing and benefiting from effective prevention  
53   and treatment services [5].

54   Self-stigmatization among PLHIV is one of the consequences of stigma from the community. The  
55   perception may force PLHIV to hide their serostatus and, in many cases, to continue engaging in  
56   high-risk behaviors [6]. Therefore, this study was conducted to assess the effect of stigmatization  
57   and self-discrimination on viral load suppression among PLHIV attending care and treatment  
58   clinics at Amana and Temeke RRHs in Dar es Salaam, Tanzania.

## 59 **Materials and methods**

### 60 **Study design and area and period of the study**

61 A hospital-based cross-sectional study was conducted in Temeke Regional Referral Hospital  
62 (RRH) and Amana RRH at the Care and Treatment Clinic (CTC) in Dar es Salaam, Tanzania,  
63 between July and August 2020. Dar es Salaam city was selected to represent the regions found in  
64 Tanzanian Mainland. Dar es Salaam is the largest city, business and the former capital of Tanzania,  
65 with an approximated population of more than five million people (almost 10% of the country's  
66 population) [7].

### 67 **Study population and sampling**

68 A total of 406 PLHIV aged above 18 years and used antiretrovirals (ARVs) for more or equal to  
69 six months and attended Amana and Temeke RRHs participated in this study. The sample size was  
70 derived using the cross-sectional formula [8] and the assumed prevalence from the previous study  
71 [9]. A systematic approach was used during the recruitment of research participants. This was done  
72 by obtaining a sampling interval "n" (total patients on CTC divided by 200). Then a patient was  
73 sampled after every "n" interval.

### 74 **Data collection tool**

75 A structured questionnaire with open and close-ended questions was prepared following an  
76 intensive literature review on a topic related to stigmatization, adherence and viral load  
77 suppression [9–11]. The English questionnaire was designed and translated to Kiswahili (local  
78 language). The Kiswahili questionnaire was uploaded on REDCap (Research Electronic Data  
79 Capture). REDCap is an electronic data capture tool hosted at Muhimbili University of Health and  
80 Allied Sciences (MUHAS) [12,13]. The questionnaire was tested on a pilot population of 30

81 patients (15 from each CTC). The updated Kiswahili questionnaire was then used to collect  
82 patients' demographics, pharmacy refill, and ART adherence factors. Data was collected using  
83 tablets and coded in the REDcap after being translated into English. REDCap data were  
84 downloaded, cleaned in excel (to remove incomplete forms), then exported to Statistical Package  
85 for Social Sciences (SPSS software version 25, Chicago Inc., USA) for analysis.

## 86 **Data management and analysis**

87 Descriptive statistics were summarized using frequencies and percentages. Stigmatization was  
88 estimated using the HIV stigma toolkit described elsewhere [14]. A Chi-square test was employed  
89 to analyze the association between categorical variables such as gender, refill interval, regimen  
90 used and HCWs preference and viral load suppression. Viral load suppression and high viral load  
91 were defined as viral load counts below 1,000 copies/ ml and above 1,000 copies/ ml, respectively  
92 [15]. Factors associated with viral load suppression were controlled using a binary regression  
93 model. Factors with a p-value less than 0.2 in univariate regression were qualified for multivariate  
94 logistic regression [16]. A p-value of less than 0.05 was considered statistically significant.

## 95 **Ethical considerations**

96 Ethical clearance was sought from the MUHAS Institutional Review Board  
97 (DA.25/111/01/10/02/2021). Temeke RRH and Amana RRH permitted the study to be conducted  
98 on their respective premises and patients. All participants provided written informed consent for  
99 participation. The consent included information on the description of the study, data privacy/  
100 confidentially and handling. Patients who reported self-discrimination and stigmatization were  
101 counseled on medication adherence. Preventive measures for the COVID-19 pandemic were  
102 observed during the whole period of data collection.

## 103 Results

104 Overall, 406 PLHIV were included in this study, with 205 PLHIV from Amana RRH and 201  
105 PLHIV from Temeke RRH. Most of the respondents were female, 298 (73.2%), and the majority  
106 (50%) were between 25 and 44 years old. The majority of the respondents, 151 (38.2%), received  
107 ART for 7 to 12 years. In addition, the majority of study respondents, 171 (42.5%), were married  
108 and most participants, 382 (94.6%), reported to be on a dolutegravir-based regimen. The majority,  
109 215 (52.8%), had a refill interval of three months (Table 1).

110 **Table 1. Participants' socio-demographic characteristics**

111

Variable	Category	Frequency N (%)
Gender (n = 406)	Female	298 (73.2)
	Male	108 (26.5)
Age (n = 404)	18 - 24	33 (8.2)
	25 - 44	202 (50.0)
	45 - 54	108 (26.7)
	55 - 64	48 (11.9)
	≥ 65	13 (3.2)
Hospital facility (n = 406)	Amana RRH	205 (50.4)

	Temeke RRH	201 (49.4)
Start ARV use (years)	< 2	80 (20.3)
(n = 395)		
	3 - 6	103 (26.1)
	7 - 12	151 (38.2)
	≥ 12	61 (15.4)
Marital status	Married	171 (42.0)
(n = 402)		
	Single	106 (26.0)
	Divorced	79 (19.4)
	Widowed	46 (11.3)
On dolutegravir based regimen	Yes	382 (94.6)
(n = 404)		
	No	22 (5.4)
Refill interval (months)	1	83 (20.4)
(n = 406)	2	7 (1.7)
	3	215 (52.8)
	6	101 (24.8)
Cost for a single hospital visit	< 2000	283 (69.9)
(TZS)		
(n = 405)		
	≥ 2000	87 (21.4)
	No cost	35 (8.6)

Waiting time at CTC (hours)	< 0.5	51 (12.6)
(n = 405)	0.5 - 1	137 (33.8)
	1 - 2	128 (31.6)
	> 2	89 (22)
Traveling time from home to CTC (hours)	< 0.5	105 (25.9)
(n = 406)	0.5 - 1	188 (46.3)
	1 - 2	91 (22.4)
	> 2	22 (5.3)

---

**Key: RRH: Regional Referral Hospital**

112

113

## 114 **Status disclosure among people living with HIV**

115 The majority of the respondents, 378 (93.1%), disclosed their HIV status. The majority, 352

116 (93.6%) of those disclosing their HIV status, were consequently encouraged to take medication.

117 Most of the participants, 246 (61.2%), reported concealing their HIV status to themselves, while

118 212 (52.7%) reported not having a reminder person or tool to assist them in taking their medication

119 on time. When asked about the reminder person or a reminder tool, the majority of the participants,

120 52.7%, reported a lack of reminders. In contrast, the remaining participants, 24.4%, said their

121 partners remind them. In comparison, 19.7% are reminded by their family members, and 6.7%

122 reported using a phone and other devices to remind them to take medication (Table 2).



123 **Table 2. Status disclosure among people living with HIV**

124

<b>Variable</b>	<b>Categories</b>	<b>Frequency (%)</b>
Disclosure of HIV status (n = 406)	Yes	378 (93.1)
	No	28 (6.9)
Response after disclosing the status	They encouraged me to take medication	352 (93.6)
	They supported me Financially and Socially	111(29.5)
	They felt stigmatized me	15 (4.0)
	They left me to deal with it alone	12 (3.2)
Preference to keep a secret their HIV status (n = 402)	Prefer to keep a secret	246 (61.2)
	Do not prefer to keep a secret	156 (38.8)
Who is the reminder person to assist in taking medication	No one reminds me	212 (52.7)
	Yes, I am reminded by someone.	168 (41.3)
	Phone alarm Reminds me.	27 (6.0)

125

126

127

## 128 **Self-discrimination and stigmatization**

129 Of all participants, 355 (87.4%) reported that they preferred having a separate HIV clinic for HIV  
130 patients. When asked for a reason, most participants, 309 (87.0%), reported that a separate HIV  
131 CTC is a free space for HIV patients. Most participants, 275 (67.9%), agreed on having HIV  
132 hospital services if the HCW was a familiar person from their neighborhood (Table 3).

133

134 **Table 3. Self-discrimination and stigmatization**

<b>Variable</b>	<b>Categories</b>	<b>Frequency (%)</b>
Preferred CTC location (n = 399)	Having separated HIV clinic	355 (87.4)
	Inclusive HIV clinic	26 (6.4)
	Anyhow is better	18 (4.4)
	None of the above	7 (1.7)
Why prefer separated HIV CTC	It is a free space for HIV patients	309 (87.0)
	I am comfortable seeing others with HIV, knowing that I am not alone	99 (27.9)
	I just like how the things are	35 (9.9)
	So as to avoid the long waiting queue at the inclusive clinic	28 (7.9)
Would you have your HIV hospital services if the health care worker is a person you know from your neighborhood? (n = 405)	Yes	275 (67.9)
	No	130 (32.1)
Why not receive the hospital service from familiar HCWs from the neighborhood	Because of the stigma that I will receive	56 (43.4)
	Because of fear that HCW will disclose my health status	53 (41.1)

---

	Because I do not prefer people who know me to know my health status	30 (23.3)
Which container is used to store the medication	Inside its container	320 (78.8)
	Anywhere but not inside its container	36 (8.9)
	Inside my handbag	34 (8.4)
	Inside plastic bag	30 (7.4)
	Inside an envelope	15 (3.7)
	Inside of the pockets of my clothes	10 (2.5)
To avoid the noise made by the containers, what do you add to the container	I am not bothered by the sound; I do not do anything	227 (73.7)
	I add a clean Handkerchief inside the container	31 (10.1)
	I add leaflet paper inside the containers	27 (8.8)
	I add clean cotton inside the container	18 (5.8)
	I only take my medication when I am at home. I do not move with them	16 (5.2)
	I do not move with medication inside the container. I keep them in the hospital plastic bags	10 (3.2)
Where do you store ARV medication at home	On top of the cupboard	123 (30.3)
	Inside clothes cupboard	118 (29.1)

---

---

Under the bed	83 (20.4)
Inside backpack	35 (8.6)
In between clothes in the suitcase	29 (7.1)
Inside dishes cupboard	19 (4.7)
Inside the refrigerator	7 (1.7)
Near the window	6 (1.5)
Inside a drawer	5 (1.2)
In the car	3 (0.7)

---

135

136

137

138

## 139 **Factors associated with viral load suppression**

140 Analysis of factors associated with viral load suppression found that viruses were more suppressed  
141 among female patients than their male counterparts ( $p = 0.036$ ). Those on the dolutegravir-based  
142 regimen also suppressed viral load more than those on other regimens ( $p = 0.050$ ). Participants  
143 with a refill interval of three months had more viral suppression than those with six months and  
144 additional months of refill interval with a  $p$ -value  $< 0.000$  ( $p = 0.004$ ) (Table 4).

145

146 **Table 4. Factors associated with viral load suppression**

147

148

149

<b>Variable</b>	<b>Category</b>	<b>Total</b>	<b>Viral load suppressed n (%)</b>	<b>High viral load n (%)</b>	<b>P value</b>
Gender n = 385	Female	282	224 (79.4)	58 (20.6)	<b>0.036*</b>
	Male	103	72 (69.9)	31 (30.1)	
Regimen (n = 383)	DBR	362	283 (78.2)	79 (21.8)	<b>0.050*</b>
	Another regimen	21	11 (52.4)	10 (47.6)	
Refill Interval	Three months	212	176 (83.3)	36 (16.3)	<b>0.000*</b>

(n = 387)	Six months	99	95 (96)	4 (4.0)
	One month	69	23 (33.3)	46 (66.7)
	Two months	7	2 (28.6)	5 (71.4)
HCW	They would continue	255	207 (81.2)	48 (18.8)
(n = 384)	with service if the HCW is a familiar person from their neighborhood			<b>0.004*</b>
	They would NOT continue with hospital service if the HCW is a familiar person from their neighborhood	129	88 (68.2)	41(31.8)

Key: \*Statistically significant by Chi-square,

HCWs: Health care workers, DBR: Dolutegravir-based regimen

150

151

152

153

## 154 **Regression analysis of factors associated with viral load suppression**

155 On a multivariate analysis, male patients were 60% less likely to have viral load suppression

156 compared to female patients (adjusted odds ratio [aOR]: 0.4, 95% confidence interval [95%]: 0.19

157 – 0.77, p = 0.007). Refill interval was significantly associated with viral load suppression. For

158 example, patients with one-month refill intervals had odds of 0.01 (95%CI: 0.003-0.42,  $p < 0.0001$ )  
159 as compared to those with six months refill intervals (Table 5).

160 **Table 5. Multinomial logistics regression of factors associated with viral load suppression**

Variable	Category	aOR (95%CI)	P value
Gender	Male	0.4 (0.19 - 0.77)	0.007*
	Female	Reference	< 0.0001*
Refill interval	One month	0.01 (0.003 – 0.42)	< 0.0001*
	Two months	0.01 (0.00 - 0.088)	< 0.0001*
	Three months	0.2 (0.054 - 0.566)	0.004*
	Six months	Reference	
Adherence	Adherent	1.2 (0.552 - 2.408)	0.705
	Non-adherent	Reference	
Name of facility	Temeke RRH	1.5 (0.735 – 3.02)	0.269
	Amana RRH	Reference	
Regimen used	DBR	1.1 (0.125 – 9.384)	0.942
	Non-DBR	Reference	

\*Statistically significant, **aOR**: Adjusted Odds Ratio, **95%CI**: 95% confidence interval,

**RRH**: Regional referral hospital, **DBR**: Dolutegravir-based regimen



## 162 **Discussion**

163 The study was conducted one year after introducing the dolutegravir-based regimen as the  
164 preferred default first line for managing HIV among adults in Tanzania [15], making the study the  
165 first to report the proportion of people who have been switched to dolutegravir-based regimens.

166 This study found that most participants (87.4 %) preferred having a separate HIV clinic for HIV  
167 patients. When asked for a reason, they responded that a separate clinic would ensure their privacy  
168 by concealing their daily medication to the community surrounding PLHIV. It was further revealed  
169 that PLHIV tends to change the containers of medication. Most PLHIV reported using plastic bags,  
170 envelopes and handbags to carry their medication. This practice impairs the quality of ARV and,  
171 in turn, may result in low viral load suppression. However, in our study, the variable did not  
172 significantly affect viral load suppression.

173 When asked where they store their medication at home, most study participants (30.3%) responded  
174 that they hide their medication in the cupboard. This was consistent with a study done in South  
175 Africa by Flynn and colleagues [17], which indicated that most participants reported using the  
176 refrigerator or a typical cupboard to store their medication [17].

177 In addition, our study revealed that 78.2% of the respondents on dolutegravir-based regimens  
178 achieved viral load suppression. This proportion is less compared to the study done in Uganda in  
179 2018, where 94% of PLHIV on dolutegravir achieved viral load suppression [5]. Also, this finding  
180 was below national data on viral load suppression, where 87.0% of adults on ART in Tanzania  
181 were reported to have suppressed viral loads [15]. However, this finding may be limited to a period  
182 of one year after the introduction of the dolutegravir regimen in Tanzania.

183 The female gender was significantly associated with viral load suppression. This is inconsistent  
184 with other studies in Uganda in 2014-2015 on factors associated with viral load non-suppression  
185 [18]. This study's significant association between viral load suppression and refill time interval  
186 may be because the Tanzania National treatment guideline prescribes that PLHIV who consistently  
187 maintain viral load suppression are given a longer refill time interval [15].

188 Most of the study participants (67.9%) agreed on having HIV hospital services if the HCW is a  
189 person they know from their neighborhood compared to the 32.1% of participants who did not  
190 agree to be served by familiar healthcare personnel. Of all PLHIV not willing to be served by a  
191 familiar HCW, 43.4% reported the fear of stigmatization, while 41.1% feared that HCW would  
192 disclose their health status. Similar results were reported in the perpetuation of stigma by HCWs  
193 may have a more significant impact on the continuum of care outcomes of PLWH in research [19].

194 There was a significant association between viral load suppression and participants' HCW  
195 preference for getting hospital service from the HCW familiar to them and coming from their  
196 neighborhood. The participants who were not particular about the HCW who served them were  
197 more likely to have viral suppression compared to those who would not continue with hospital  
198 service if the HCW was a familiar person from their neighborhood [20].

199 Our results are based on the self-reported perception of stigma. Self-reported data is usually  
200 subject to potential recall bias and social desirability. To minimize this bias, some  
201 information, such as socio-demographic characteristics and viral load information, was  
202 obtained from hospital records. Also, patients were requested to skip questions they did not  
203 remember rather than guessing the responses.

## 204 **Conclusion**

205 Elements of self-perceived stigma appeared to influence the viral load suppression among PLHIV  
206 in Dar es Salaam, Tanzania. Factors such as gender and refill time interval were significantly  
207 associated with viral load suppression among HIV patients in the Dar es Salaam region. More  
208 counseling on stigmatization and its effects on PLHIV is needed to stop self-stigmatization.

## 209 **Acknowledgments**

210 We thank all the participants who agreed and consented to participate in this study. We also thank  
211 health care providers at Centres for Treatment and Counselling for their dedicated cooperation  
212 during the data collection phase.

213

## 214 **References**

- 215 1. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al.  
216 Enhanced adherence counselling and viral load suppression in HIV seropositive patients  
217 with an initial high viral load in Harare, Zimbabwe: Operational issues. Mor O, editor.  
218 PLoS One. 2019;14: e0211326. doi:10.1371/journal.pone.0211326
- 219 2. Omosanya OE, Elegbede OT, Agboola SM, Isinkaye AO, Omopariola OA. Effects of  
220 Stigmatization/Discrimination on Antiretroviral Therapy Adherence among HIV-Infected  
221 Patients in a Rural Tertiary Medical Center in Nigeria. J Int Assoc Provid AIDS Care.  
222 2014;13: 260–263. doi:10.1177/2325957413475482
- 223 3. Bernays S, Papparini S, Seeley J, Rhodes T. “Not Taking it Will Just be Like a Sin”: Young

- 224 People Living with HIV and the Stigmatization of Less-Than-Perfect Adherence to  
225 Antiretroviral Therapy. *Med Anthropol.* 2017;36: 485–499.  
226 doi:10.1080/01459740.2017.1306856
- 227 4. Tsai AC, Bangsberg DR, Kegeles SM, Katz IT, Haberer JE, Muzoora C, et al. Internalized  
228 Stigma, Social Distance, and Disclosure of HIV Seropositivity in Rural Uganda. *Ann*  
229 *Behav Med.* 2013;46: 285–294. doi:10.1007/s12160-013-9514-6
- 230 5. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High  
231 acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in  
232 pilot sites in Uganda: A mixed-methods prospective cohort study. Torpey K, editor. *PLoS*  
233 *One.* 2020;15: e0232419. doi:10.1371/journal.pone.0232419
- 234 6. Dean Wantland W-TC. Engagement with Health Care Providers Affects Self- Efficacy,  
235 Self-Esteem, Medication Adherence and Quality of Life in People Living with HIV. *J*  
236 *AIDS Clin Res.* 2013;04: 1–14. doi:10.4172/2155-6113.1000256
- 237 7. United Republic of Tanzania. National Beaural of Statistics: 2012 Population and Housing  
238 Census Population Distribution by Administrative areas. *Natl Bur Stat Minist Financ.*  
239 2013; 177,180.
- 240 8. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical  
241 studies. *Gastroenterol Hepatol from bed to bench.* 2013;6: 14–7.
- 242 9. Sangeda RZ, Mosha F, Aboud S, Kamuhabwa A, Chalamilla G, Vercauteren J, et al.  
243 Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment  
244 center in Tanzania. *Drug Healthc Patient Saf.* 2018;10: 79–88.  
245 doi:10.2147/DHPS.S143178
- 246 10. Dehens J, de Hemptinne M, Galouchka M, Sajud A, van Otzel RP, Vanhoorebeeck C, et

- 247 al. Exploring the value and acceptability of peer support in the process of improving  
248 adherence to HIV antiretroviral drugs in Tanzania, Dar-es-Salaam. *Transdiscipl Insights*.  
249 2017;1: 9–32. doi:10.11116/TDI2017.1.2
- 250 11. Mosha F, Ledwaba J, Ndugulile F, Ng’ang’a Z, Nsubuga P, Morris L, et al. Clinical and  
251 virological response to antiretroviral drugs among HIV patients on first-line treatment in  
252 Dar-es-Salaam, Tanzania. *J Infect Dev Ctries*. 2014;8: 845–52. doi:10.3855/jidc.3879
- 253 12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap  
254 consortium: Building an international community of software platform partners. *J Biomed*  
255 *Inform*. 2019;95: 103208. doi:10.1016/j.jbi.2019.103208
- 256 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data  
257 capture (REDCap)--a metadata-driven methodology and workflow process for providing  
258 translational research informatics support. *J Biomed Inform*. 2009;42: 377–81.  
259 doi:10.1016/j.jbi.2008.08.010
- 260 14. USAID. Understanding and Challenging HIV Stigma toward Entertainment Workers.  
261 2007 [cited 19 Aug 2021] p. 143. Available: [https://www.icrw.org/wp-](https://www.icrw.org/wp-content/uploads/2016/10/Understanding-and-Challenging-HIV-Stigma-toward-Entertainment-Workers-Toolkit-for-Action.pdf)  
262 [content/uploads/2016/10/Understanding-and-Challenging-HIV-Stigma-toward-](https://www.icrw.org/wp-content/uploads/2016/10/Understanding-and-Challenging-HIV-Stigma-toward-Entertainment-Workers-Toolkit-for-Action.pdf)  
263 [Entertainment-Workers-Toolkit-for-Action.pdf](https://www.icrw.org/wp-content/uploads/2016/10/Understanding-and-Challenging-HIV-Stigma-toward-Entertainment-Workers-Toolkit-for-Action.pdf)
- 264 15. United Republic of Tanzania. National Guidelines for the management of HIV and AIDS  
265 in Tanzania. 2019 [cited 30 May 2021]. Available:  
266 [http://www.nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-](http://www.nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-aids/)  
267 [aids/](http://www.nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-aids/)
- 268 16. Kilipamwambu A, Bwire GM, Myemba DT, Njiro BJ, Majigo M V. WHO/INRUD core  
269 prescribing indicators and antibiotic utilization patterns among primary health care

- 270 facilities in Ilala district, Tanzania. *JAC-Antimicrobial Resist.* 2021;3: 1–7.
- 271 doi:10.1093/jacamr/dlab049
- 272 17. Flynn AD, Scheuerle RL, Galgon G, Gerrard SE, Netshandama VO. An assessment of  
273 infant medication administration and storage practices in selected communities in the  
274 Vhembe District of Limpopo Province, South Africa. *Heal SA Gesondheid.* 2019;24: 1–7.  
275 doi:10.4102/hsag.v24i0.1075
- 276 18. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors  
277 Associated with Virological Non-suppression among HIV-Positive Patients on  
278 Antiretroviral Therapy in Uganda, August 2014–July 2015. *BMC Infect Dis.* 2017;17:  
279 326. doi:10.1186/s12879-017-2428-3
- 280 19. Algarin AB, Sheehan DM, Varas-Diaz N, Fennie KP, Zhou Z, Spencer EC, et al. Health  
281 Care-Specific Enacted HIV-Related Stigma’s Association with Antiretroviral Therapy  
282 Adherence and Viral Suppression Among People Living with HIV in Florida. *AIDS*  
283 *Patient Care STDS.* 2020;34: 316–326. doi:10.1089/apc.2020.0031
- 284 20. Kiekens A, Dehens J, de Hemptinne M, Galouchka M, Vanhoorebeeck C, van Otzel RP,  
285 et al. HIV-related Peer Support in Dar es Salaam: A Pilot Questionnaire Inquiry.  
286 *Transdiscipl Insights.* 2019;3: 1–18. doi:10.11116/TDI2019.3.1

